Deficient DNA Mismatch Repair

• Deficient DNA Mismatch Repair (dMMR) is a cellular defect preventing the correction of DNA replication errors.
• It leads to an accumulation of mutations, primarily in microsatellite regions, known as microsatellite instability (MSI).
• Causes include inherited mutations (Lynch syndrome) and acquired somatic mutations in MMR genes.
• dMMR is a significant driver of several cancer types, notably colorectal and endometrial cancers.
• Identifying dMMR is crucial for cancer diagnosis, prognosis, and guiding targeted immunotherapies.

What is Deficient DNA Mismatch Repair?

What is deficient DNA mismatch repair? It refers to a condition where the cellular machinery responsible for correcting specific errors in DNA, known as the DNA mismatch repair (MMR) system, is not functioning properly. The MMR system acts as a crucial proofreading mechanism, identifying and repairing incorrect base pairings or small insertions/deletions that arise spontaneously during DNA replication. When this system is deficient, these errors accumulate, leading to a high mutation rate, particularly in repetitive DNA sequences called microsatellites. This phenomenon is known as microsatellite instability (MSI), a hallmark of dMMR.

The integrity of the MMR system is vital for maintaining genomic stability. Its deficiency allows mutations to persist, some of which can occur in genes that regulate cell growth and division, thereby promoting the development and progression of cancer. Understanding dMMR is fundamental in oncology, as it has profound implications for cancer risk assessment, diagnosis, and treatment strategies.

Causes of DNA Mismatch Repair Deficiency

The primary Deficient DNA mismatch repair causes can be broadly categorized into two main types: inherited and sporadic (acquired). Inherited dMMR is predominantly associated with Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC). Lynch syndrome is an autosomal dominant genetic condition caused by germline mutations in one of the MMR genes, most commonly MLH1, MSH2, MSH6, or PMS2, or by deletions in EPCAM leading to MSH2 silencing. The Centers for Disease Control and Prevention (CDC) estimates that Lynch syndrome affects about 1 in 279 individuals, making it the most common inherited cause of colorectal cancer and endometrial cancer.

Sporadic dMMR, on the other hand, is acquired during an individual’s lifetime and is not passed down through generations. The most common cause of sporadic dMMR is the methylation of the MLH1 gene promoter, which silences its expression. This epigenetic modification prevents the production of the MLH1 protein, rendering the MMR system non-functional. Sporadic dMMR is frequently observed in approximately 15% of all colorectal cancers and a significant proportion of endometrial cancers, often presenting in older individuals without a strong family history of cancer.

Clinical Impact and Cancer Risk

The clinical impact of dMMR is primarily manifested through its strong association with an increased risk of developing various cancers. While there are no direct Deficient DNA mismatch repair symptoms, the deficiency leads to specific cancer types with characteristic features. Individuals with dMMR, particularly those with Lynch syndrome, have a significantly elevated lifetime risk of developing cancers, most notably colorectal cancer, endometrial cancer, ovarian cancer, gastric cancer, small bowel cancer, hepatobiliary tract cancer, urinary tract cancer, and certain brain tumors.

The DNA mismatch repair deficiency cancer link is well-established. For instance, dMMR is found in about 15% of all colorectal cancers and approximately 20-30% of endometrial cancers, according to data from the National Cancer Institute (NCI). Tumors with dMMR often exhibit unique pathological features and tend to have a better prognosis in early stages compared to MMR-proficient tumors. Crucially, dMMR status has become a vital biomarker for predicting response to specific immunotherapies, particularly checkpoint inhibitors. Patients with dMMR cancers, regardless of their tumor type, often respond favorably to these treatments due to the high mutational burden and increased neoantigen presentation resulting from the repair defect.

Identifying dMMR through molecular testing (e.g., immunohistochemistry for MMR proteins or PCR for MSI) is therefore a standard practice in the management of several cancer types, guiding treatment decisions and enabling genetic counseling for individuals and families at risk of inherited dMMR syndromes.